For decades, many of the medical guidelines used in India have been based on research conducted in Europe and North America. While those studies have advanced healthcare globally, they do not always reflect the realities of Indian patients.
Recognising this gap, the Indian Council of Medical Research (ICMR), the country’s top biomedical research body, is planning India first clinical trials initiative.
This initiative intends to fund large multi-centre clinical trials designed around Indian populations with the goal of generating health info that is more relevant to local healthcare needs.
For a country with more than 1.46 billion people, the move could play an important role in shaping future treatment guidelines, healthcare policies, and patient outcomes.
Why is ICMR taking this step?
The answer is simple: India needs more evidence generated from Indian patients.
Many treatment recommendations currently followed across the country are based on international studies done primarily in Europe and North America.
While these studies remain valuable, they often involve populations with differences in genetic makeup, diet, environment and lifestyle.
And these differences can significantly influence how diseases develop and how people respond to treatments. What works for one population may not necessarily produce the same results in another.
By supporting large-scale domestic clinical trials, ICMR intends to build a stronger evidence base that better represents India’s diverse population and healthcare challenges.
What does India first clinical trials include?
ICMR plans to support extensive clinical trials conducted across multiple hospitals and research institutions throughout the country.
The studies are expected to focus on some of India’s biggest health challenges, including:
- Diabetes
- Cardiovascular diseases
- Cancer
- Other chronic and non-communicable diseases
According to information shared by health experts, eligible clinical trials could receive funding of up to ₹8 crore over a four-year period.
The idea is to generate research that can directly inform healthcare decisions in India.
What this means for patients
For patients, the biggest benefit is relevance.
Future treatment guidelines could increasingly be based on evidence collected from people who share similar genetic, cultural, dietary, and lifestyle characteristics.
Instead of relying primarily on data generated elsewhere, doctors would have access to findings that are super relevant to Indian populations.
The impact won’t be immediate. Clinical trials take time, and translating research into practice is a gradual process.
However, as new evidence emerges, it could help healthcare professionals make more informed decisions while also supporting policies that better address India’s unique disease burden.
Over the long term, this could improve how diseases are diagnosed, managed, and treated across the country, ultimately leading to more effective and patient-centred care.
A major opportunity for researchers and hospitals
The initiative also creates new opportunities for collaboration across India’s healthcare and research ecosystem.
Large multi-centre studies bring together hospitals, universities, and research organisations, allowing them to collect broader and more diverse datasets. This can help researchers better understand how diseases vary across regions, demographics, and patient groups.
Beyond generating stronger evidence, such collaborations can also strengthen India’s overall clinical research infrastructure and capabilities.
Has the implementation started?
The programme has been announced, and ICMR has indicated its intention to provide financial support for eligible studies.
The next phase will involve identifying suitable research projects and launching clinical trials at participating institutions.
As with any large-scale initiative, success will depend on execution. It’ll be interesting to see how quickly studies can begin, how efficiently they can be completed, and how effectively their findings can be incorporated into clinical practice and public health policy.
If implemented successfully, the initiative could help establish a robust foundation of India-specific medical evidence over the coming years.
Looking ahead
India’s healthcare challenges are unique, shaped by its vast population, regional diversity, and growing burden of chronic diseases.
As these challenges continue to evolve, there’s a high need for locally generated evidence.
Through this initiative, ICMR signals a shift toward research designed around Indian patients rather than adapted from elsewhere. If the programme delivers on its promise, it could influence everything from treatment protocols and public health strategies to future healthcare innovation.
More importantly, it could help ensure that medical decisions in India are guided by evidence that truly reflects the people they are meant to serve.
